PB1280 Excellent Real World Experience using Damoctocog Alfa Pegol

ISTH Academy, Faculty / Presenters, 406921

PB1281 Natural History of Hepatitis C Virus (HCV) Infection in Korean Hemophilic Cohort

ISTH Academy, Faculty / Presenters, 406922

PB1265 “HERMES” - HEmophilia Related MEntal illnesS: A Cross-Sectional, Multicenter Study in Switzerland

ISTH Academy, Faculty / Presenters, 406923

PB1282 Real-World Unmet Needs of Adult Patients with Severe Hemophilia A without Inhibitors in Poland: How to Select the Optimal Therapy?

ISTH Academy, Faculty / Presenters, 406924

PB1268 Clinical Outcomes with Octocog Alfa in Patients with Hemophilia A in China: 1-year of Follow-up of the AHEAD International Study

ISTH Academy, Faculty / Presenters, 406925

PB1269 Comorbidities - An Additional Burden in the Real Life of Patients with Haemophilia

ISTH Academy, Faculty / Presenters, 406926

PB1270 Hematopoietic Stem Cell Transplantation in a Newborn Suffering from Severe Combined Immunodeficiency and Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 406927

PB1272 Impact of the Difference in the Cutoff Point of the Values of Clotting Factors VIII and IX in the Definition of Women with Hemophilia and Hemophilia Carrier

ISTH Academy, Faculty / Presenters, 406928

PB1273 Inhibitor Recurrence on Emicizumab Prophylaxis in Tolerized Patients with Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 406929

PB1274 Joint Health in Patients with Hemophilia: Data from Real Life Practice in Colombia

ISTH Academy, Faculty / Presenters, 406930

PB1275 Multicenter and Cross-Sectional Study of Joint Damage of Patients with Non-Severe Hemophilia: A “Mediterranean Group” Study

ISTH Academy, Faculty / Presenters, 406931

PB1277 Thrombin Generation and Clot Formation and Lysis Properties in Hemophilia A with and without Emicizumab

ISTH Academy, Faculty / Presenters, 406932

PB1278 Real-World Data on Hemophilia A Patients with Inhibitors Switching to Either BAY 94-9027 or BAY 81-8973 in the ATHNdataset

ISTH Academy, Faculty / Presenters, 406933

PB1254 A New Tool to Assist in Treatment Selection - The World Federation of Hemophilia (WFH) Shared Decision-Making (SDM) Tool

ISTH Academy, Faculty / Presenters, 406934

PB1255 An Update on Real-World use of rVIII-SingleChain in Patients with Haemophilia A in Germany: Interim Results from a Prospective, Non- Interventional Study

ISTH Academy, Faculty / Presenters, 406935

PB1256 Complication Analysis in Korean Patients with Hemophilia A from 2007 to 2019: A Nationwide Study by the Health Insurance Review and Assessment Service Database

ISTH Academy, Faculty / Presenters, 406936

PB1257 Diagnostic Tool for Patients with Hemophilia: from Bedside to Comprehensive Investigation

ISTH Academy, Faculty / Presenters, 406937

PB1258 Discrepancies Between Laboratory Assays in Hemophilia A Pediatric Patients Receiving Prophylaxis

ISTH Academy, Faculty / Presenters, 406938

PB1259 Emicizumab Prophylaxis: A Novel Alternative Therapy for Severe Hemophilia A Patients with and without Inhibitors

ISTH Academy, Faculty / Presenters, 406939

PB1260 Importance of Molecular Diagnostics to Classify the Severity of Hemophilia A: A Brief Experience of Fundaçâo Hemominas in Brazil

ISTH Academy, Faculty / Presenters, 406940

PB1261 Matching Adjusted Indirect Comparisons Between Personalized Prophylaxis with Simoctocog Alfa versus Standard Prophylaxis with Turoctocog Alfa in Adults with Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 406941

PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study

ISTH Academy, Faculty / Presenters, 406942

PB1264 Thrombin Generation Assay as a Treatment Tracking Tool in Hemophilia Patients: a Retrospective Cohort Study

ISTH Academy, Faculty / Presenters, 406943

PB1241 ATHN 11: Observational Study of Long-Term Outcomes of Liver Transplantation

ISTH Academy, Faculty / Presenters, 406944

PB1243 Comparison of Quality of Life and Bleeding Phenotypes in People with Congenital Hemophilia A: Longitudinal Study from the PicnicHealth Database of PROMIS®-29 v2.0 Scores

ISTH Academy, Faculty / Presenters, 406945

PB1244 Early Joint Damage Detection in Pediatric Patients with Moderate and Severe Hemophilia: Usefulness for Treatment Individualization

ISTH Academy, Faculty / Presenters, 406946

PB1245 Efficacy, Safety and Dosing of Pasteurized Plasma-Derived von Willebrand Factor/Factor VIII Concentrate for the Treatment of von Willebrand Disease: A Systematic Review

ISTH Academy, Faculty / Presenters, 406947

PB1247 Iron Deficiency in Inherited Bleeding Disorders in a Hemophilia Center

ISTH Academy, Faculty / Presenters, 406948

PB1248 Patient-Reported Outcomes Using the Patient-Reported Outcomes, Burdens and Experiences Survey Following Emicizumab Initiation in Patients with Severe Hemophilia A without Inhibitors at a Single Centre

ISTH Academy, Faculty / Presenters, 406949

PB1249 Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 406950

PB1250 Quality of Life in Females and Males with Mild Congenital Hemophilia A: A Longitudinal Study from the PicnicHealth Database of PROMIS®- 29 v2.0 Scores

ISTH Academy, Faculty / Presenters, 406951

PB1251 The Use of Extended Half-Life Factor IX Products in the Surgical Setting - A UK Hemophilia Center Experience

ISTH Academy, Faculty / Presenters, 406952

PB1252 Value of Hemophilia Drug Treatment Using Analysis of the Area Under the Curve

ISTH Academy, Faculty / Presenters, 406953

PB1238 Improvement of Haemorrhagic Outcomes after Changing Paradigm Treatment of Haemophilia in the Real World: Six Years of Experience in a Portuguese Comprehensive Care Centre

ISTH Academy, Faculty / Presenters, 406954

PB1239 Prophylaxis with Extended Half-life Products in Patients with Hemophilia A: Real-life Data of the Milan Cohort

ISTH Academy, Faculty / Presenters, 406955

PB0685 A Retrospective Review of Heavy Menstrual Bleeding in Women with Inherent Bleeding Disorders - A Need for Joint Gynaecology-Haematology Clinic

ISTH Academy, Faculty / Presenters, 406956

PB0686 Clinical Decisions and Factors Influencing the Management of Persons with Hemophilia Requiring Antithrombotic Therapy: A Qualitative Study

ISTH Academy, Faculty / Presenters, 406957

PB0689 Efficacy/Effectiveness of Extended Half-Life Factor VIII Concentrates on the Prophylaxis of People with Hemophilia A: A Systematic Review and Meta-Analysis

ISTH Academy, Faculty / Presenters, 406958

PB0687 Comorbidities in an Aging Bleeding Disorder Population: A Retrospective Comparison Study

ISTH Academy, Faculty / Presenters, 406959

PB0690 Factor X Consumption Could Cause Attenuation of Emicizumab Effect; A Case Report of Severe Hemophilia A with Inhibitor Treated by Emicizumab and Factor VIII-Bypassing Agents

ISTH Academy, Faculty / Presenters, 406960

PB0691 Inhibitor Eradication Strategies in Patients with Non-Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 406961

PB0692 Matching-Adjusted Indirect Comparison of rIX-FP versus rFIXFc for Prophylactic Treatment of Hemophilia B

ISTH Academy, Faculty / Presenters, 406962

PB1236 Real World Experience of Perioperative Management in People with Hemophilia Receiving Extended Half Life FVIII and FIX Concentrates: A Multicentric and Cross-Sectional Study in Northern Spain

ISTH Academy, Faculty / Presenters, 406963

PB1237 Validation of a Semi-Automated Von Willebrand Multimer Assay for Use in VWD Classification

ISTH Academy, Faculty / Presenters, 406964

PB0679 Clinical Characteristics and Disease Outcomes in Previously Treated Patients with Haemophilia: Results from a Real-World Study in Europe and United States

ISTH Academy, Faculty / Presenters, 406965

PB0680 Clinical Characteristics, Therapy and Outcome of Children with Hemophilia B and Inhibitors: a PedNet Study

ISTH Academy, Faculty / Presenters, 406966

PB0681 German Experience with Simoctocog alfa during Surgery in Female Haemophilia A Carriers

ISTH Academy, Faculty / Presenters, 406967

PB0682 In Vitro Response to Bypassing Agents and Long Term Follow-up of Patients with Severe Hemophilia A on Prophylaxis with Emicizumab

ISTH Academy, Faculty / Presenters, 406968

PB0683 Patients at Higher Risk of Spontaneous Joint Bleeding during Emicizumab Prophylaxis: A Study on Global Coagulation Assays and Arthropathy Scores

ISTH Academy, Faculty / Presenters, 406969

PB0684 Quality of Life in Patients & Caregivers Living with Hemophilia A without Inhibitors in Spain, Interim Analysis of the HEMOLIFE Study

ISTH Academy, Faculty / Presenters, 406970

PB0665 5 Years of Prophylaxis with Emicizumab in Children and Adults with Hemophilia A with and without Inhibitors in a Portuguese Hemophilia Center - Outcomes in Bleeding and Surgery

ISTH Academy, Faculty / Presenters, 406971

PB0666 Clinical Outcomes Following Treatment with Octocog Alfa in Patients with Hemophilia A: 9-Year Interim Read-Out of the Real-World AHEAD International Study

ISTH Academy, Faculty / Presenters, 406972

PB0667 Development and Clinical Utility of Anti-Emicizumab Antibody Detection Assays

ISTH Academy, Faculty / Presenters, 406973

PB0668 Emicizumab Treatment Regimen Based on Vial Size Along with Quantification of Emicizumab Plasma Concentration. Real-World Experience from a Single Pediatric Center in Argentina

ISTH Academy, Faculty / Presenters, 406974

PB0669 Final Analysis of Long-Term Clinical Outcomes of Recombinant Factor IX Fc Fusion Protein Prophylaxis in Adults ≥50 Years with Severe Hemophilia B

ISTH Academy, Faculty / Presenters, 406975

PB0670 Nationwide Survey on the Care Reality of People with Mild Hemophilia A and B in Germany - The Burden of Mild Hemophilia

ISTH Academy, Faculty / Presenters, 406976

PB0671 Poor Correlation between Biomarkers and MRI-Detected Joint Damage in a Cross-Sectional Study of Persons with Non-Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 406977

PB0672 Real-World Data on Hemophilia A Patients Switching to Either BAY 94-9027 or BAY 81-8973 from Emicizumab Using the ATHNdataset

ISTH Academy, Faculty / Presenters, 406978

PB0674 The Impact of Suboptimal Adherence to Factor Replacement Therapy on Time Spent Below Target Factor Trough Levels: Simulations Using Population Pharmacokinetic Modeling

ISTH Academy, Faculty / Presenters, 406979

PB0675 The Reverse Two-Sample in One-Clinic Visit Factor VIII Pharmacokinetic Protocol Using myPKFiT: the Brazilian Experience

ISTH Academy, Faculty / Presenters, 406980

PB0653 Can Thrombin Generation Assays be Used to Guide the Use of Anticoagulants in People with Haemophilia? - An Exploratory Study

ISTH Academy, Faculty / Presenters, 406981

PB0654 Combined Point of Care Tools Improve Treatment Adherence and Health-Related Quality of Life in Patients with Hemophilia Under Regular Prophylaxis: An Observational Mulicenter Prospective Study

ISTH Academy, Faculty / Presenters, 406982

PB0656 Impact of Moderate to Vigorous-Intensity Physical Activities on Pharmacokinetic-Guided Extended Half-Life FVIII Concentrates Prophylaxis Severe Hemophilia A Patients

ISTH Academy, Faculty / Presenters, 406983

PB0657 Is Implementation of Pharmacokinetic-Guided Dosing of Factor Replacement Therapy in Bleeding Disorders on TARGET? A Scoping Review to Map Barriers and Facilitators

ISTH Academy, Faculty / Presenters, 406984

PB0658 Low-Dose Immune Tolerance Induction in Patients with Hemophilia A and Inhibitor Receiving Emicizumab Prophylaxis: Preliminary Results of the Brazilian Experience

ISTH Academy, Faculty / Presenters, 406985

PB0659 Patients with Hemophilia A have Increased Levels of Circulating Activated Protein C: Potential Contribution to their Hemostatic Status

ISTH Academy, Faculty / Presenters, 406986

PB0661 Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Canadian Patients with Hemophilia A: Interim Results from the HEM-POWR Study

ISTH Academy, Faculty / Presenters, 406987

PB0663 Risk Factors for Atherosclerosis in Patients with Hemophilia

ISTH Academy, Faculty / Presenters, 406988

PB0664 Treatment Adherence in Young People with Hemophilia: Perceptions of UK Healthcare Professionals

ISTH Academy, Faculty / Presenters, 406989

PB0641 Association between Physical Activity and Bleeding Events in People with Hemophilia A Receiving Emicizumab Prophylaxis: Interim Analysis of the TSUBASA Study

ISTH Academy, Faculty / Presenters, 406990

PB0642 Determinants of the Bleeding Phenotype in Persons with Non-Severe Hemophilia

ISTH Academy, Faculty / Presenters, 406991

PB0643 Efficacy of Emicizumab Prophylaxis in Patients with Severe Hemophilia A in Germany: Follow-up Evaluation of Real-Life-Data Documented by Smart Medication eDiary

ISTH Academy, Faculty / Presenters, 406992

PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study

ISTH Academy, Faculty / Presenters, 406993

PB0645 Evaluation of the Effect of Factor VIII on the Measurement of Emicizumab Levels in Plasma

ISTH Academy, Faculty / Presenters, 406994

PB0646 Feasibility of Self-Ultrasound Scanning of the Knee Joint in Untrained Individuals: Can Artificial Intelligence Help?

ISTH Academy, Faculty / Presenters, 406995

PB0647 Life Expectancy and Mortality of Patients with Haemophilia A and Haemophilia B in Australia

ISTH Academy, Faculty / Presenters, 406996

PB0648 Mitigating the Risk of Bleeds and the Risk for Inhibitor Formation when Treating Previously Untreated Patients (PUPs) with Severe Haemophilia A - A Single-Centre Approach

ISTH Academy, Faculty / Presenters, 406997

PB0649 Results from the RESIST Study for Tolerance Induction in Patients with Poor Prognosis for ITI Success

ISTH Academy, Faculty / Presenters, 406998

PB0650 Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Pediatric Patients with Hemophilia B: A Review of Results from Phase 3 Trial Studies

ISTH Academy, Faculty / Presenters, 406999

PB0651 The Axis NETosis-Activated Protein C May Modulate the Hemostatic Status of Patients with Hemophilia A

ISTH Academy, Faculty / Presenters, 407000

PB0634 A Phase 3, Single-Arm, Multicenter, Open-Label, One-Way Crossover Study to Evaluate the Efficacy and Safety of Fitusiran Prophylaxis in People with Severe Hemophilia A or B, with or without Inhibitors

ISTH Academy, Faculty / Presenters, 407001

PB0635 A Usability Study Assessing Handling and Preference of the Concizumab Pen-Injector in Patients with Haemophilia and Caregivers

ISTH Academy, Faculty / Presenters, 407002

PB0636 Clinical Outcomes Following Treatment with Octocog Alfa in Patients with Severe Hemophilia A and Pre-Existing Target Joints: 9-year Interim Read-Out of the Real-World AHEAD International Study

ISTH Academy, Faculty / Presenters, 407003

PB0637 Epidemiological, Clinical and Radiological Profile of Articular Pathology (Joint Disease) in the Cameroonian Haemophiliac

ISTH Academy, Faculty / Presenters, 407004

PB0638 Final Data from A-MOVE: 12-Month Prospective Multicentre Study to Investigate the Impact of Systematic Joint Examination on Treatment Management Decisions in Patients with Hemophilia A in France

ISTH Academy, Faculty / Presenters, 407005

PB0639 Haemophilia; Ageing and Frailty

ISTH Academy, Faculty / Presenters, 407006

PB0640 Safety and Efficacy of Combined Dual Antiplatelet Therapy and FVIII Prophylaxis in Hemophilia A Patients after the Acute Coronary Syndrome

ISTH Academy, Faculty / Presenters, 407007

PB0629 Designing the Efanesoctocog Alfa Module of ATHN Transcends: Safety, Tolerability, and Effectiveness in Previously Untreated Patients with Hemophilia A

ISTH Academy, Faculty / Presenters, 407008

PB0630 Final Analysis of Long-Term Clinical Outcomes of Prophylaxis with a Recombinant Factor VIII Fc Fusion Protein in Adults Aged ≥50 Years with Severe Hemophilia A

ISTH Academy, Faculty / Presenters, 407009

PB0632 Quality of Life Outcomes Following Treatment with Octocog Alfa in Patients with Hemophilia A: 9-Year Interim Read-Out of the Real- World AHEAD International Study

ISTH Academy, Faculty / Presenters, 407010

PB0633 Understanding the Requirement for Additional Factor VIII Infusion Associated with Novel Haemophilia A Treatments: An Expert Elicitation Exercise

ISTH Academy, Faculty / Presenters, 407011

PB0627 Management of Invasive Procedures in Patients with Hemophilia A Receiving Emicizumab Prophylaxis: Real-World Data from a National Hemophilia Treatment Center

ISTH Academy, Faculty / Presenters, 407012

PB0620 (Mis)Labeling Hemophilia Severity: Exploring the Illness Cognitions of Persons with Hemophilia

ISTH Academy, Faculty / Presenters, 407013

PB0628 The World Federation of Hemophilia Living Guidelines Model

ISTH Academy, Faculty / Presenters, 407014

PB0621 Emicizumab Plasma Concentrations are not Related to Bleeding Rates Using Standard Dosing, a Call for Dose Adaptation

ISTH Academy, Faculty / Presenters, 407015

PB0622 A Report of the Measurement of Steady State Emicizumab Levels in an Irish Cohort of Persons with Severe Haemophilia A

ISTH Academy, Faculty / Presenters, 407016

PB0623 An Enriched Population Pharmacokinetic Model for Recombinant Factor IX-Fc Fusion Including Young Children with Haemophilia B

ISTH Academy, Faculty / Presenters, 407017

PB0624 A-SURE: Intra-Patient Comparison of Prophylactic Effectiveness of a Recombinant Factor VIII Fc Fusion Protein Versus Standard Half-Life Factor VIII in Hemophilia A

ISTH Academy, Faculty / Presenters, 407018

PB0625 Emicizumab Prophylaxis in People with Hemophilia A Aged >50 Years withComorbidities:ExperienceFromtheATHN7Hemophilia Natural History Study

ISTH Academy, Faculty / Presenters, 407019

PB0626 Quantitative Pharmacokinetic Model to Characterize and Extrapolate Long-Term FVIII Activity Levels in Patients with Severe Hemophilia A Treated with Valactocogene Roxaparvovec

ISTH Academy, Faculty / Presenters, 407020